Results 71 to 80 of about 1,064,547 (319)

Gut microbiota: emerging biomarkers and potential therapeutics for premature ovarian failure

Frontiers in Microbiology
Premature ovarian failure is a prevalent gynecological endocrine disorder with an increasing incidence rate each year, impacting women’s physical and mental health.
Zongyu Liu, Zongyu Liu, Min Wang, Min Wang, Yuanyuan Lei, Yuanyuan Lei, Kaiqi Xu, Kaiqi Xu, Kaiqi Xu, Limei Fan, Limei Fan   +10 more
doaj   +1 more source

Association Between Dinutuximab Beta Exposure and Post‐End‐of‐Treatment Survival in Neuroblastoma: A Weighted Patient‐Level Analysis of Three Clinical Studies

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Objectives The association between exposure to dinutuximab beta (DB) and event‐free survival (EFS) or overall survival (OS) of neuroblastoma patients was assessed using data collected during three clinical trials (five cohorts). Methods A systematic review (March 2026) was conducted to identify relevant studies (prospective; registered DB ...
Przemysław Holko, Holger N. Lode, Alberto Garaventa, Carla Manzitti, Roberto Luksch, Dominique Valteau‐Couanet, Marion Gambart, John Anderson, Juliet Gray, Adela Canete, Lucas Moreno, Aleksandra Wieczorek, Cormac Owens, Shifra Ash, Isaac Yaniv, Genevieve Laureys, Hans Loibner, Katarzyna Śladowska, Ruth Ladenstein, Paweł Kawalec   +19 more
wiley   +1 more source

Therapeutics Letter 70 [PDF]

, 2008
Therapeutics Letter 70 summarizes the top five most accessed Cochrane reviews in 2007. Topics include prevention of fall in elderly people, treating obesity in children, low glycaemic diets for overweight and obesity, and nicotine receptor partial ...
Therapeutics Initiative (University of British Columbia)
core  

Targeted degradation of GSPT1 and NEK7 by a molecular glue prodrug for treatment of HCC

Communications Chemistry
Targeted Protein Degradation (TPD) technology, in the form of CRBN-modulating molecular glues, offers numerous unprecedented therapeutic benefits as evidenced by the success of approved high-value immunomodulatory imide drugs (IMiDs) such as lenalidomide
Przemysław Glaza, Roman Pluta, Krzysztofa E. Odrzywół, Marta Klejnot, Maria Wieczorek, Sylvain Cottens, Donald Coppen, Paweł Dobrzański, Tomas Drmota, Joanna Lis-Grześniak, Agata Śnieżewska, Joanna Majkut, Martyna Mianowska, Paulina Rozborska, Marta Jarmuszkiewicz, Katarzyna Kaczanowska, Aleksandra Adamska, Toshimitsu Takagi, Anna Sawicka, Anna Serwotka-Suszczak, Olga Makowska, Daria Gajewska, Kinga Jurczak, Kinga Leszkowicz, Michał Mankiewicz, Kamil Przytulski, Janusz Wiśniewski, Anna Szlachcic, Michał J. Walczak   +28 more
doaj   +1 more source

Lichenoid dysplasia treated by apremilast - report of two cases and review of literature

Journal of Family Medicine and Primary Care
Lichenoid dysplasia (LD) is a distinct clinicopathologic condition characterized by bilateral or unilateral oral lesions with a lichenoid pattern and atypical cells, giving it a higher risk for malignant transformation. Unlike oral lichen planus (OLP) or
Shiladitya Sil, Rudra Pyne, Sayani Shome, Soumyajit Dutta   +3 more
doaj   +1 more source

Long‐Term Outcomes of Patients With Relapsed/Refractory Neuroblastoma Treated on ANBL1221: A Report From the Children's Oncology Group

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Results of COG ANBL1221 changed treatment paradigms for patients with relapsed/refractory neuroblastoma. Chemoimmunotherapy with irinotecan/temozolomide/dinutuximab is now used as both bridge therapy following suboptimal response to induction and as treatment in first relapse.
Elizabeth Sokol, Arlene Naranjo, Lulu Chen, Rajen Mody, Steven G. DuBois, Rochelle Bagatell, Navin Pinto   +6 more
wiley   +1 more source

Therapeutics Letter 1 [PDF]

, 1994
Therapeutics Letter 1 addresses common questions, including dosage, about H2-blockers for treatment of non-ulcer dyspepsia in adults. Other than cost, there is little difference between the four H2-blockers (Cimetidine, Famotidine, Nizatidine, and ...
Therapeutics Initiative (University of British Columbia)
core  

Immune cells in Alzheimer’s disease: insights into pathogenesis and potential therapeutic targets

Medical Review
Alzheimer’s disease (AD) is a chronic neurodegenerative disorder for which there are currently no effective treatment options. Increasing evidence suggests that AD is a systemic disease closely associated with the immune system, not merely a central ...
Fu Xiaofeng, Cai Huimin, Quan Shuiyue, Ren Ziye, Xu Yinghao, Jia Longfei   +5 more
doaj   +1 more source

Measurable Residual Disease Monitoring During Treatment for Pediatric Acute Myeloid Leukemia in First Relapse

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Survival after relapse in pediatric acute myeloid leukemia (AML) remains poor, highlighting the critical importance of identifying prognostic factors to guide optimal relapse management. Methods We investigated the prognostic impact of multiparameter flow cytometry (MFC) measurable residual disease (MRD) in 188 patients with first ...
Camilla Poulsen, Kristian Juul Sandahl, Lene Karlsson, Jonas Abrahamsson, Nira Arad‐Cohen, Daniel Cheuk, Barbara De Moerloose, Linda Fogelstrand, Jose Maria Fernandez Navarro, Bianca F. Goemans, Kirsi Jahnukainen, Gertjan Kaspers, Zhanna Kovalova, Monica Cheng Munthe‐Kaas, Ulrika Norén‐Nyström, Josefine Palle, Ramune Pasauliene, Cornelis Jan Pronk, Kadri Saks, Anne Tierens, Henrik Hasle, Kristian Løvvik Juul‐Dam   +21 more
wiley   +1 more source

Therapeutics Letter 28 [PDF]

, 1999
Therapeutics Letter 28 explores the role of angiotensin II receptor blockers in hypertension and congestive heart failure. Conclusions: Angiotensin receptor blockers act to modulate the renin angiotensin pathway at a different site compared to ACE ...
Therapeutics Initiative (University of British Columbia)
core